DES and DCB with Similar Results in Femoropopliteal Artery Disease

Courtesy of Dr. Carlos Fava.

Nowadays, peripheral interventions are on the rise and the technological development of stents and balloons would help achieve better outcomes. Both drug-eluting stents (DES) and drug-coated balloons (DCB) have proved to be beneficial for femoropopliteal interventions, but the actual role of each of these technologies remains unclear.

DES de 2.0 mm para vasos muy pequeños: ¿Es viable?This prospective, randomized 1:1 study included 15 patients with intermittent claudication, femoropopliteal lesions, and Rutherford functional categories 2 to 5.

 

The devices used were the Zilver PTX platform stent (Cook Medical) and the In.Pact Admiral or In.Pact Pacific balloon (Medtronic Vascular).

 

Patient characteristics between groups were similar: the mean age was 69; 24% of patients had diabetes; most were classified as category 2-3; 20% had renal insufficiency; lesion length was 150 mm, and half the patients had total occlusions.


Read also: AHA 2018 | New-Generation DES Are Similar to Second-Generation DES Beyond Polymer.


In the DCB group, the bailout was 25%. Additionally, ≥30% residual lesions were also more frequent in that group.

 

Primary patency at 12 months was similar between groups (79.9% DEB, 79.3% DES; rate difference 0.6%; 95% confidence interval [CI]: 13% to 14.2%; p = 0.96) and there was a trend in favor of DES at 3 years. There were no differences as regards mortality or amputations. Improvement was similar for both groups.

 

Conclusion

Patency at 12 months, effectiveness, and safety of DES versus DCB plus bailout stenting in femoropopliteal interventions are comparable. There was a trend in favor of DES over DCB at 36 months.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Drug-Eluting Stent Versus Drug-Coated Balloon Revascularization in Patients with Femoropopliteal Arterial Disease.

Reference: Yvonne Bausback et al. J Am Coll Cardiol 2019;73:667-79.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...